Spots Global Cancer Trial Database for In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)

Official Title: In Vitro Evaluation of Immune Responses in CTCL

Study ID: NCT00177190

Conditions

Cutaneous T-cell Lymphoma

Sezary Syndrome

Mycosis Fungoides

Interventions

Study Description

Brief Summary: This is an in vitro evaluation of cutaneous T-cell lymphoma using patients' blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/CD 8 cells.

Detailed Description: This is an in vitro evaluation of cutaneous T-cell lymphoma using patients blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/ CD 8 cells with the following objectives: * Objective I: Evaluate the feasibility of the preparation of dendritic cells (DCs), CD8 and Sezary cells (all CD4 positive) in vitro, obtained from the buffy coats or a skin biopsy from an area with tumor involvement of subjects with cutaneous t-cell lymphoma (CTCL) and Sezary syndrome (leukemic stage of CTCL) undergoing an approved FDA therapy, extracorporeal photopheresis (ECP). * Objective II: Evaluate antigen loading of the DCs. * Objective III: Test the functional capacities of the DCs derived from CTCL subjects to overcome immune tolerance to the tumor cells ex-vivo, by using modified Elispot assay in conjunction with Granzyme B Elispot assay as a measurement of cytotoxicity.